Castle Minerals Limited (CDT)
CXA 
Summary
CDT Equity Inc. (NASDAQ:CDT) Short Interest Update
CDT Equity Inc. (NASDAQ: CDT - Get Free Report) was the target of a significant growth in short interest in February. As of February 27th, there was short interest totaling 177,766 shares, a growth of 140.0% from the February 12th total of 74,063 shares. Approximately 8.4% of the shares of the stock are sold short. Based
CDT Environmental Technology Announces Private Placement of Common Stock
SHENZHEN, China, Jan.
CDT Environmental Technology Reports 2025 Unaudited Interim Financial Results and Provides Business Updates
Revenue of $7.3 million and loss per share of $0.11 impacted by reduced project activity due to a slowdown in the PRC economy SHENZHEN, China, Dec.
Castle Minerals Limited (CDT) FAQ
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Castle Minerals Limited ever had a stock split?
Castle Minerals Limited Profile
| Biotechnology Industry | Healthcare Sector | Andrew Regan CEO | CXA Exchange | US20678X5023 ISIN |
| US Country | 6 Employees | - Last Dividend | 27 Mar 2026 Last Split | - IPO Date |
Overview
Conduit Pharmaceuticals Inc., established in 2019 and situated in San Diego, California, emerges as a clinical-stage specialty biopharmaceutical company committed to addressing the unmet medical demands in autoimmune diseases and idiopathic male infertility. As a subsidiary of Corvus Capital Limited, Conduit Pharmaceuticals leverages its expertise and innovative approaches to develop novel pharmaceutical solutions. The company's dedication to advancing medical treatment options is evident in its dynamic research and development activities, focusing on creating impactful therapies for patients grappling with complex health conditions.
Products and Services
- AZD1656
This advanced compound has successfully concluded Phase I trials, showcasing its potential as a versatile treatment option for several health issues. Primarily, AZD1656 is being explored for its efficacy in managing type 2 diabetes, a prevalent condition affecting millions worldwide. Additionally, its application extends to renal transplant patients, offering the prospects of improved outcomes. Autoimmune thyroid disorders such as Hashimoto's thyroiditis and Grave's disease, along with uveitis and preterm labor, are also part of the drug's comprehensive trial phase. Each of these areas represents critical health challenges, underscoring AZD1656's promise in providing relief and better management options for diverse patient populations.
- AZD5904
Conduit Pharmaceuticals has also developed AZD5904, a groundbreaking compound that has completed Phase I clinical trials, targeting idiopathic male infertility. Understanding the complex nature of male infertility and the lack of effective treatments, this development signifies a beacon of hope. AZD5904's progression through the clinical trial phases reflects the company's commitment towards novel medical solutions, potentially revolutionizing the approach to treating idiopathic male infertility and improving the live of affected individuals.
